Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Does This Patient Have Myasthenia Gravis?

Does This Patient Have Myasthenia Gravis? ContextClinicians must be able to diagnose myasthenia gravis, since delays in establishing the diagnosis may put patients at risk for complications from this treatable disease.ObjectiveTo determine if items in the history and examination or results of simple tests change the likelihood of myasthenia gravis as a diagnosis.Data SourcesMEDLINE search of English-language articles (January 1966-January 2005) using the terms myasthenia gravis, diagnosis, and test, and a search of bibliographies of retrieved articles.Study SelectionStudies evaluating a particular symptom or sign in patients both with and without myasthenia gravis. Of 640 articles retrieved, 33 were eligible for review. Of these, 15 met inclusion criteria and form the basis of this review.Data ExtractionTwo authors independently reviewed each study to determine eligibility, abstracted data using a standardized instrument, and classified study quality using previously published criteria.Data SynthesisA history of “speech becoming unintelligible during prolonged speaking” and the presence of the peek sign increase the likelihood of myasthenia gravis (likelihood ratio [LR], 4.5; 95% confidence interval [CI], 1.2-17.0 and LR, 30.0; 95% CI, 3.2-278.0, respectively). Their absence does not significantly reduce the likelihood of myasthenia gravis. The identified studies only assessed 1 other historical feature and sign each (“food remaining in the mouth after swallowing” and quiver eye movements, respectively), and neither of these significantly changes the likelihood of myasthenia. The ice test is useful when the response is abnormal (summary positive LR, 24.0; 95% CI, 8.5-67.0) and diminishes the likelihood of myasthenia gravis when the response is normal (summary negative LR, 0.16; 95% CI, 0.09-0.27). A positive response to an anticholinesterase medication (mainly edrophonium test) increases the probability of a diagnosis of myasthenia gravis (summary positive LR, 15.0; 95% CI, 7.5-31.0), and a negative response reduces the diagnostic probability of myasthenia (summary negative LR, 0.11; 95% CI, 0.06-0.21). An abnormal sleep test result is useful in confirming the diagnosis (LR, 53.0; 95% CI, 3.4-832.0). The rest and sleep tests make the probability of myasthenia unlikely when results are normal (LR, 0.52; 95% CI, 0.29-0.95 and LR, 0.01; 95% CI, 0.00-0.16, respectively).ConclusionsItems in the history and physical examination along with results of certain simple tests performed in the office (ice test, sleep test, and edrophonium test) are useful in predicting the likelihood of myasthenia gravis. These results must be interpreted with caution, however, given the high prevalence of disease in the populations reported in clinical studies. This review is limited by the small number of signs and symptoms scientifically studied and reported in the literature. Future studies evaluating the value of common historical features and easy maneuvers commonly known and practiced by experts in the clinical diagnosis of myasthenia are needed.CLINICAL SCENARIOSCase 1A 45-year-old man has a 2-month history of fluctuating double vision, a “droopy” right eye that improves with rest, and a complaint that “food gets stuck halfway down.” Your examination confirms severe right eyelid ptosis that dramatically improves with rest. His right eye adduction and upgaze are markedly impaired. The left eye demonstrates complete horizontal ophthalmoplegia. The limb muscle strength and reflexes are normal. You wonder whether there is an accurate and clinically useful bedside test to help confirm the diagnosis of myasthenia gravis.Case 2A 69-year-old man has a 2-month history of intermittent spells of double vision, generalized weakness that worsens toward the evening, and unspecified dizziness. Although he has normal strength and reflexes and no ophthalmoplegia, he does report fluctuating diplopia during the examination. As in Case 1, you must decide whether to perform additional bedside tests, obtain electrodiagnostic or acetylcholine antibody testing, or pursue a broader diagnostic evaluation of the various causes of dizzy spells and fatigue.WHY IS THIS AN IMPORTANT QUESTION TO ANSWER WITH A CLINICAL EXAMINATION?Myasthenia gravis is an autoimmune disease associated with circulating acetylcholine receptor antibodies, modification of the synaptic cleft, and destruction of the postsynaptic neuromuscular membrane. The clinical hallmark of the disease is fatigable weakness. The clinical severity ranges from mild, purely ocular, forms to severe generalized weakness and respiratory failure. Myasthenia gravis is a rare disease; its prevalence in the United States is reported at 14.2/100 000. Prevalence rates have been increasing steadily over the past decades, likely due to decreased mortality, longer survival, and higher rates of diagnosis.Men older than 50 years have the highest incidence in the population, with the peak around age 70 years. Women have 2 incidence peaks: one around ages 20 to 40 years and one around age 70 years.Clinicians must be alert to the symptoms and signs of myasthenia gravis, as it is an eminently treatable disease and the earlier treatment is started, the better the clinical response.Only 54% to 69% of patients with myasthenia gravis are diagnosed within 1 year of onset, and the mean time to diagnosis is more than 1 year.Untreated patients are at risk for deterioration and “crisis,” which occurs when weakness becomes severe enough to require mechanical ventilation.Left untreated, reversible and fatigable weakness may become fixed. An erroneous diagnosis of myasthenia gravis may expose patients to unnecessary diagnostic procedures and treatments.The acetylcholine receptor antibody test is the most specific diagnostic test for myasthenia gravis. This test has reasonable sensitivity in generalized myasthenia gravis (80%-96%), but up to 50% of patients with purely ocular myasthenia are seronegative.Single-fiber electromyography, performed by highly trained experts at specialized centers, is highly sensitive for disorders of the neuromuscular junction but is not specific for myasthenia gravis.The purpose of this review was to determine the value of clinical symptoms and signs, as well as the results of simple provocative clinical tests, in deciding whether myasthenia gravis should be considered as a diagnosis and in enabling the physician to determine if further confirmatory testing (including the highly specific and sensitive antibody test) is warranted.Anatomical and Physiological Origins of the Symptoms and Signs Used to Answer This QuestionIn the normal neuromuscular junction acetylcholine is released into the synaptic cleft, diffuses to the postsynaptic membrane, binds to ligand-sensitive ion channels (nicotinic acetylcholine receptors), and causes an excitatory postsynaptic end-plate potential. If the threshold depolarization is achieved, an action potential will spread along the muscle fiber membrane, causing muscle contraction. Acetylcholine is cleared from the synaptic cleft by presynaptic reuptake and by the metabolic action of acetylcholinesterase (Figure 1).Figure 1.Neuromuscular JunctionIn patients with acetylcholine receptor (AChR) antibody–positive myasthenia gravis, circulating antibodies bind to the AChRs, which may block acetylcholine binding, lead to crosslinking of receptors promoting internalization and degradation, and induce postsynaptic membrane damage via complement activation. The number and availability of receptors are reduced such that end-plate potentials are insufficient to generate action potentials in a number of muscle fibers, causing weakness.The failure of transmission at many neuromuscular junctions in myasthenia results in diminished end-plate potentials that are insufficient to generate action potentials in a number of muscle fibers.This results in fatigable weakness of striated muscles, which is the basis for the clinical diagnosis. Sustained or repetitive muscle contraction causes fatigue and weakness of myasthenic muscles. Cooling a weak muscle improves neuromuscular transmission.Rest and acetylcholinesterase inhibitors transiently increase acetylcholine levels in the synaptic cleft. The change in strength following these manipulations can be assessed during the clinical examination.Symptoms and Signs and How to Elicit ThemPatients with myasthenia gravis complain of weakness in specific muscles. Up to 65% of patients initially have ocular symptoms of double vision and drooping of the eyelids. Less than one fourth of patients present with bulbar weakness (ie, in lower cranial nerve–innervated oropharyngeal muscles) and report slurred or nasal speech, alterations of the voice (eg, softness, breathiness, hoarseness), and difficulty chewing or swallowing. Limb weakness is a rare initial complaint (14%-27%) and should be differentiated from nonspecific generalized fatigue. Patients may report shortness of breath. The symptoms of myasthenia are typically better upon awakening or after rest and become progressively worse with prolonged use of the affected muscles or later in the day.Reduced muscle power by manual testing in specific muscles that worsens with repetition and improves with rest is the characteristic examination finding in myasthenia. Most muscles with voluntary activation have a large variability of strength even under normal conditions due to effort. Evaluating extremity strength greatly depends on the experience of the examiner. Ptosis and extraocular muscle deficits are relatively free of a voluntary component and provide a more objective measure.Fatigable and rapidly fluctuating asymmetric ptosis is a hallmark of myasthenia gravis. The rapid fluctuation results from improvement during even very short periods of rest, such as blinking. Besides fast variability in the degree of ptosis, it may altogether shift quickly from one eye to the other, known as “shifting ptosis.”Ptosis should be evaluated with the patient sitting comfortably, the head held in primary position without tilting. The patient fixates on a distant object (eg, a spot on the wall) and is asked to refrain from blinking and to relax the forehead muscles. Frontalis contraction, a mostly involuntary compensatory mechanism, is a common and characteristic sign in myasthenic patients with ptosis. Relaxing the forehead muscles may be difficult for some patients. The examiner measures palpebral fissure width at eye level during forward gaze and again during prolonged upward or lateral gaze for 30 seconds.The more ptotic eyelid should be used for additional provocative tests, such as the ice pack, rest, and sleep tests.The ice pack test is performed by placing a latex glove finger filled with crushed ice over the more ptotic eyelid for 2 minutes. During the rest test the patient places a glove filled with cotton (a placebo) over the more ptotic eyelid while holding the eyes closed for 2 minutes. During the sleep test the patient is left in a quiet dark room with the eyes closed for 30 minutes. Complete or almost complete resolution of ptosis or at least a 2-mm increase in palpebral fissure width constitutes a positive response to these maneuvers. It is very important to evaluate the improvement immediately following the test, as the lids may quickly begin to droop again.The curtain sign (also known as “enhanced ptosis” or “paradoxical ptosis”) is usually observed in patients with some initial ptosis. The patient looks straight ahead and refrains from blinking. The examiner holds one eye open, which results in the other lid starting to droop more (like a curtain falling). The lid twitch sign occurs when the patient opens the eyes after gentle closure or follows the examiner’s finger down and then back up to eye level. The lids overshoot or “twitch” for a fraction of a second before settling into position and starting to droop.Asymmetrical weakness of extraocular muscles is commonly observed in myasthenia when sustained lateral gaze or upgaze worsens or induces double vision. The cover-uncover test may be performed to bring out subtle extraocular weakness. As the patient fixates on an object in the distance, the examiner covers one eye while observing for deviation of the uncovered eye during lateral and then upward gazing. With extraocular weakness, the uncovered eye will drift. The examination is completed by repeating the procedure for the opposite eye. Quiver eye movements are very fast, small-twitch, “lightning-” or “jerk”-like movements of the eyes upon changing direction of gaze. They are said to occur even in the setting of profound ophthalmoplegia.Although patients rarely complain of facial weakness, it is often found on examination. Severe facial weakness results in a characteristic transverse smile. Orbicularis oculi weakness is demonstrated as the examiner tries to separate the eyelids against forced eye closure. Orbicularis oculi fatigue may be observed on gentle eye closure. After complete initial apposition of the lid margins, they separate within seconds and the white of the sclera starts to show (positive “peek sign”) (Figure 2).The iris should not be visible due to the eyeballs being rolled up (Bell phenomenon). The iris may be visible if the patient is not trying to close the eyes voluntarily (in the case of a conversion reaction and functional weakness) or in case of severe ophthalmoplegia.Figure 2.Peek SignOrbicularis oculi weakness may be indicated by a positive peek sign after gentle eyelid closure. After complete initial apposition of the lid margins, they quickly (within 30 seconds) start to separate and the sclera starts to show (ie, a positive peek sign). The presence of a peek sign increases the likelihood of myasthenia gravis (likelihood ratio, 30.0; 95% confidence interval, 3.2-278.0), but absence of the peek sign does not rule it out.Tongue and pharyngeal weakness will result in the patient’s speech becoming slurred or nasal, especially with prolonged speaking. Other commonly weak muscles include neck flexors, deltoids, hip flexors, finger/wrist extensors, and foot dorsiflexors. The muscles should be repeatedly tested against manual resistance, with a brief rest between repetitions. Having the patient hold the head above the pillow in the supine position or hold the arms outstretched in abduction at the shoulder for 1 minute are ways to test for fatigability of neck flexors and deltoids, respectively. Involvement is often asymmetrical. The remainder of the neurologic examination results, including those for deep tendon reflexes and sensory examination, must be normal.Anticholinesterase TestsEdrophonium chloride is a fast- and short-acting acetylcholinesterase inhibitor that may be administered in the office setting to diagnose myasthenia gravis (Box). Its effect usually occurs within 30 seconds and lasts less than 5 minutes. Most myasthenic muscles respond to the test dose of 2 mg, but many will require more. Adverse effects are rare and usually mild (excess salivation, sweating, abdominal cramps, or fecal incontinence). Serious adverse effects, such as bradycardia, asystole, and bronchoconstriction, occur infrequently (<0.2%) but warrant that the patient be receiving cardiac monitoring during the test and that a bag-mask be available should the patient need ventilatory assistance.Reactive airway disease or cardiac bradyarrhythmias are relative contraindications. Using a 3-way stopcock setup may be feasible in a patient already equipped with a peripheral intravenous line (in an intensive care unit, for example). One concern with such a setup is the possibility of an accidental mix-up of the syringes, with resultant injection errors—the syringes should always be labeled clearly. Due to the short action of the drug, the examiner must be able to quickly assess for improvement. Evaluating extraocular muscle abnormalities or changes in manual muscle testing require skill and time; therefore, most experts recommend performing the edrophonium test only when the patient has easily observed baseline weakness in specific muscles.One author feels that only a clearly ptotic eyelid or visibly abnormal extraocular muscles provide “objective” end points.Unequivocal improvement in ptosis or extraocular muscles constitutes a positive response. The administering physician (especially one with less experience) should consider blinding the edrophonium administration to avoid expectation bias.Box. Edrophonium TestEstablish reliable peripheral intravenous accessPrepare a syringe with 2 mg of atropine (available in 0.4-mg/mL or 1-mg/mL ampules) to have handyPrepare 1 mL (10 mg) of edrophonium in a tuberculin syringe (edrophonium is available in a 10-mg/mL solution in a 1-mL ampule [10 mg] or in a 10-mL vial [total of 100 mg])Inject 2 mg (0.2 mL) slowly over 15 seconds while observing for an objective improvement in target musclesImprovement should occur within 30 seconds and disappear in 5 minutes; if no response and no significant adverse effects, administer the remaining edrophonium (8 mg [0.8 mL]) for a total dose of 10 mgAtropine should be injected (0.5 or 1 mg) in case of clinically significant bradycardia, respiratory distress, or syncope**Routine administration of atropine simultaneously with edrophonium for the purpose of diagnostic testing for myasthenia gravis is not recommended. Bartley and Bullockrecommend using a 3-way stopcock with the edrophonium-containing syringe attached to the direct port and the atropine-containing syringe attached to the side port, so that atropine may be quickly injected in case of severe adverse effects.Neostigmine bromide is an anticholinesterase agent used to treat myasthenia gravis. Parenteral preparations are available in vials containing 0.25-, 0.5-, and 1-mg/mL doses. The recommended dose for the diagnosis of myasthenia is 0.02 mg/kg given intramuscularly. A standard dose of 1 or 1.5 mg may be used. The response should be evaluated 30 minutes after injection, at the time of peak effect. The half-life after intramuscular administration is 50 to 90 minutes. Adverse effects, precautions, and need for good intravenous access (to administer atropine in case of an adverse event) are the same as for edrophonium.Pyridostigmine bromide is an analog of neostigmine with a slightly longer duration of action and fewer adverse effects. It is the most commonly used anticholinesterase agent for the symptomatic treatment of myasthenia gravis. It has been used for diagnosis in patients in whom edrophonium or neostigmine is relatively contraindicated though it is not generally used for diagnostic purposes.It is available for injection in 2-mL vials containing 5 mg/mL. A 2-mg intramuscular or intravenous dose is equivalent to 60 mg orally. Precautions should be exercised just as with edrophonium and neostigmine.METHODSSearch Strategy and Quality ReviewEnglish-language articles in the MEDLINE database from January 1966 through January 2005 were searched using the terms myasthenia gravis, diagnosis,and test. One of the authors (K.S.) identified potential articles by screening the retrieved titles and abstracts (when available) and searching through the bibliographies of the retrieved articles. Two authors (K.S., R.S.B.) independently reviewed the retrieved articles. An article was included where agreement existed that the study had met our inclusion criteria.Eligible studies evaluated a particular symptom or sign in patients with myasthenia gravis and in controls. Studies requiring sophisticated equipment or subspecialty trained physicians (otolaryngology, ophthalmology, etc) were excluded. Studies based on small numbers of patients were not excluded, as most series are comparatively small in the literature. Out of 640 total articles, the search identified 33 potential articles. Of these, 15 met inclusion criteria and form the basis of this review.Quality of evidence in each study was classified based on a published classification scheme for levels of evidence developed for The Rational Clinical Examination series (Table 1). In addition, studies that were carried out prospectively and/or on a consecutive series of patients were ranked higher (Table 2). Only 2 studies included an independent blinded comparison of signs and symptoms to a criterion standard.Table 1.Levels of Evidence*RecommendationLevel of EvidenceDefinitionGrade A1Independent, blinded comparison of sign or symptom results with a criterion standard of diagnosis among a large number of consecutive patients suspected of having the target conditionGrade B2Independent, blinded comparison of sign or symptom with a criterion standard of diagnosis among a small number of consecutive patients suspected of having the target conditionGrade C3Independent, blinded comparison of sign or symptom with a criterion standard of diagnosis among nonconsecutive patients suspected of having the target condition4Nonindependent comparison of sign or symptom with a criterion standard of diagnosis among samples of patients who obviously have the target condition plus, perhaps, normal individuals5Nonindependent comparison of sign or symptom with a standard of uncertain validity*Modified from Holleman and Simel.Table 2.Characteristics of Studies That Include Patients With Myasthena Gravis as Well as ControlsSourceEnrollmentPatient SelectionPatients With Myasthenia Gravis, No./Overall (%)Diagnostic Criteria for Myasthenia GravisSymptom or Sign Studied (Inclusion Criteria)Enrollment SiteEvidence Level 2Kubis et al,2000ProspectiveConsecutive10/25 (40)AChRAb or SFEMGIce test, rest test (ptosis)Neuro-ophthalmology clinicEvidence Level 3Ertas et al,1994ProspectiveUnclear12/27 (44)GestaltIce test, edrophonium or neostigmine test (ptosis)Neurology clinicCzaplinski et al,2003ProspectiveUnclear5/10 (50)AChRAb and RNSIce test, edrophonium test (ptosis)Neurology clinicEvidence Level 4Sethi et al,1987UnclearUnclear10/17 (59)GestaltIce test, edrophonium test (ptosis)Neurology clinicOdel et al,1991UnclearUnclear42/68 (62)Edrophonium testSleep test (ptosis or ophthalmoplegia)Ophthalmology clinicGolnik et al,1999ProspectiveUnclear20/40 (50)AChRAb or edrophonium testIce test (ptosis)Neuro-ophthalmology clinicEllis et al,2000ProspectiveConsecutive15/30 (50)GestaltIce test (ptosis or abnormal extraocular movements)Ophthalmology clinicLertchavanakul et al,2001ProspectiveUnclear20/40 (50)EMG or neostigmine testIce test (ptosis)Ophthalmology clinicEvidence Level 5Osserman and Kaplan,1952ProspectiveUnclear15/50 (30)GestaltEdrophonium testNeurology clinic, hospitalYee et al,1976ProspectiveUnclear10/18 (56)Edrophonium or neostigmine testQuiver eye movements (ophthalmoplegia)Ophthalmology clinicOsher and Griggs,1979ProspectiveConsecutive25/275 (9)UnclearPeek sign (orbicularis oculi fatigue)Ophthalmology clinicNicholson et al,1983ProspectiveConsecutive46/75 (61)Gestalt with 1 positive test resultEdrophonium testAchRab laboratoryBatocchi et al,1997ProspectiveConsecutive39/72 (54)Gestalt with 2 positive test resultsEdrophonium test (ptosis, ophthalmoplegia)Ophthalmology clinicPadua et al,2000ProspectiveConsecutive29/69 (42)AChRAb + SFEMG or RNS + AChEIEdrophonium or pyridostigmine testNeurology clinicWeijnen et al,2000UnclearUnclear60/80 (75)GestaltFood in mouth after swallowing, unintelligible speech after prolonged speakingOromaxillofacial surgery clinicAbbreviations: AChRAb, acetylcholine receptor antibody; AChEI, acetylcholine esterase inhibitor; EMG, electromyography; Gestalt, overall clinical impression; RNS, repetitive nerve stimulation; SFEMG, single-fiber electromyography.Statistical MethodsSensitivity was defined as the proportion of patients with myasthenia gravis who had the particular symptom or sign; specificity, as the proportion of nonmyasthenic patients without the sign or symptom. The positive likelihood ratio (LR) was defined as the likelihood of a positive test result (or presence of a sign or symptom) in a myasthenic patient compared with the likelihood of a positive test result in a nonmyasthenic patient, that is, the increase in odds that the patient has myasthenia gravis when the test result is positive (or when the sign or symptom is present). Positive LR is expressed as sensitivity/(1 − specificity). The negative LR is the likelihood of a negative test result (or absence of a sign or symptom) in a myasthenic patient compared with the likelihood of a negative test result (or absence of a sign or symptom) in a nonmyasthenic patient, that is, the decrease in odds that the patient has myasthenia gravis when the test result is negative (or when the sign or symptom is absent). Negative LR is expressed as (1 − sensitivity)/specificity. Summary LRs were derived using random-effects measures that provide conservative confidence intervals (CIs) around the estimates.RESULTSFifteen studies reported findings on patients both with and without myasthenia gravis(Table 2). Seven studies evaluated the ice test, including 3 that also evaluated the response to anticholinesterase agents and 1 that also evaluated the rest test. Four additional studies reported on the response to anticholinesterase agents and 1 additional study on the sleep test. The remaining 3 articles included 1 study reporting on 2 symptoms and 2 studies evaluating 1 sign each. The results across studies for the ice test and anticholinesterase tests were homogeneous; we report random-effects summary LRs for these signs (Table 3).Table 3.Clinical Signs and Symptoms and Results of Clinical Tests in the Prediction of Myasthenia GravisSourceLR (95% CI)PositiveNegativeSymptomsFood in mouth after swallowingWeijnen et al13.0 (0.85-212.0)0.70 (0.58-0.84)Unintelligible speech after prolonged speakingWeijnen et al4.5 (1.2-17.0)0.61 (0.46-0.80)SignsPeek signOsher and Griggs30.0 (3.2-278.0)0.88 (0.76-1.0)Quiver eye movementsYee et al4.1 (0.22-75.0)0.82 (0.57-1.2)Simple Office TestsIce testKubis et al28.0 (1.8-427.0)0.14 (0.03-0.62)Ertas et al31.0 (2.0-472.0)0.04 (0.00-0.61)Czaplinski et al11.0 (0.77-158.0)0.09 (0.01-1.3)Sethi et al12.0 (0.83-185.0)0.24 (0.08-0.72)Golnik et al33.0 (2.1-515.0)0.22 (0.10-0.50)Ellis et al31.0 (2.0-475.0)0.03 (0.00-0.46)Lertchavanakul et al39.0 (2.5-605.0)0.07 (0.01-0.33)Summary24.0 (8.5-67.0)0.16 (0.09-0.27)Anticholinesterase testErtas et al28.0 (1.8-436.0)0.12 (0.03-0.54)Czaplinski et al9.0 (0.61-133.0)0.27 (0.07-1.1)Sethi et al12.0 (0.83-185.0)0.24 (0.08-0.72)Osserman and Kaplan70.0 (4.4-1096.0)0.03 (0.00-0.46)Nicholson et al54.0 (3.5-850.0)0.10 (0.04-0.24)Batocchi et al67.0 (4.3-1053.0)0.01 (0.00-0.16)Padua et al9.7 (3.8-25.0)0.04 (0.01-0.28)Summary15.0 (7.5-31.0)0.11 (0.06-0.21)Rest testKubis et al16.0 (0.98-261.0)0.52 (0.29-0.95)Sleep testOdel et al53.0 (3.4-832.0)0.01 (0.00-0.16)Abbreviations: CI, confidence interval; LR, likelihood ratio.Accuracy of Symptoms for the Diagnosis of Myasthenia GravisOnly 1 eligible study was identified and it evaluated 2 symptoms.The history was taken from patients via a questionnaire. The presence of food remaining in the mouth after swallowing increases the likelihood of myasthenia gravis, but the wide CI indicates that the finding is not reliable. Speech becoming unintelligible during prolonged speaking has an LR of 4.5 (95% CI, 1.2-17.0). Neither normal swallowing nor normal speech rules out myasthenia gravis (LR, 0.70; 95% CI, 0.58-0.84 and LR, 0.61; 95% CI, 0.46-0.80, respectively).Accuracy of Signs for the Diagnosis of Myasthenia GravisTwo eligible studies were identified and reported on 1 sign each.The presence or absence of quiver eye movements increased the likelihood of myasthenia gravis, but the broad CIs around the LR indicate that the examiner may not rely on the finding. The presence of the peek sign might be more useful (LR, 30.0; 95% CI, 3.2-278.0) but also has broad CIs.Accuracy of Simple Office Tests for the Diagnosis of Myasthenia GravisSeven studies investigated the ice test and all had similar findings.The overall prevalence (prior probability) of myasthenia gravis in these studies was 49% (92 of 189 patients total). All but 1 of these studies were carried out prospectively. The LR for a positive ice test result suggests that the finding is useful (summary LR, 24.0; 95% CI, 8.5-67.0). A negative ice test result lessens the likelihood of myasthenia gravis (summary LR, 0.16; 95% CI, 0.09-0.27).Two studies evaluated the precision (ie, interobserver variation) of the ice test. Kubis et alused the signed-rank test to evaluate interobserver variability and found no significant difference between observers (P = .79). Ertas et alreported complete agreement among their observers. Neither of the studies evaluated the intraobserver variation.Seven studies reported the results of anticholinesterase tests, and all had similar findings.Five of these studies evaluated the edrophonium test; 1 study included response to pyridostigmine, and another included response to neostigmine as an alternative. All but 1 of these studies were prospective and 3 were carried out on consecutive patients. One hundred fifty-six of 320 patients (49%) had myasthenia gravis. The likelihood of myasthenia gravis increases for a positive test result (summary LR, 15.0; 95% CI, 7.5-31.0), whereas the lack of improvement makes myasthenia gravis much less likely (summary LR, 0.11; 95% CI, 0.06-0.21).Two studies evaluated the sleep or rest test on 93 patients, including 52 (56%) with myasthenia gravis.An abnormal rest test result increases the likelihood of myasthenia but the wide CI indicates uncertainty about the true significance. A positive sleep test result may be more useful (LR, 53.0; 95% CI, 3.43-832.0). Both the rest and sleep test make the probability of myasthenia unlikely when the result is normal (LR, 0.52; 95% CI, 0.29-0.95 and LR, 0.01; 95% CI, 0.00-0.16, respectively).Are These Symptoms or Signs Ever Normal?Fluctuating weakness (ie, reduced muscle power) that worsens with exertion and improves with rest or with application of ice or cold is never normal. It is important to differentiate fluctuating weakness from patients’ reports of “weakness,” which most often refers to fatigue or exertion. True fluctuating weakness, as demonstrated by manual muscle testing, is the cardinal feature of myasthenia gravis. Other neuromuscular conditions (including amyotrophic lateral sclerosis and periodic paralyses) may be associated with fluctuating weakness; however, the fluctuation in myasthenia is more dramatic and occurs much more rapidly. Ptosis or diplopia may be present in a number of conditions (congenital exotropia or esotropia, strabismus, congenital ptosis, cranial nerve palsies, myopathies, progressive external ophthalmoplegia, brainstem lesions, and neurodegenerative disorders such as progressive supranuclear palsy), but the constant degree of involvement and associated neurologic findings (pupillary abnormalities, nystagmus, vertigo, sensory involvement) commonly exclude myasthenia gravis as a diagnosis. One must bear in mind that even the initially fluctuating weakness of myasthenia gravis will become fixed over time if severe enough. The hypomimia (“masked facies”) of parkinsonism may be mistaken for facial weakness, but on examination no true weakness is found and associated features of parkinsonism are evident. It may be a challenge to differentiate true fatigable weakness due to myasthenia gravis from conversion reactions. In the latter conditions one may often find that various elements of the examination are inconsistent with pathophysiologic conditions. Conversion reactions commonly produce “give-away” weakness, in which an initial full resistance suddenly gives away under the hand of the examiner, as opposed to true weakness that gradually worsens or is present from the start. Ptosis produced by conversion reactions is commonly symmetrical and bilateral. Since it occurs with contraction of the orbicularis oculi, one can observe that the lower lid elevates. It may completely disappear with diverting the patient’s attention. Eye closure weakness due to poor effort results in the iris showing between the eyelids.RESOLUTION OF CLINICAL SCENARIOSCase 1Fluctuating diplopia and ptosis are highly characteristic of myasthenia gravis. The presence of a positive rest test result may increase the likelihood of myasthenia. The physician must carefully question the patient regarding his complaint of “food getting stuck halfway down.” If it is food remaining in the mouth after swallowing, it may also increase the probability of myasthenia. The available evidence-based data, however, do not allow the examiner to rely on these findings to confirm the diagnosis. These positive test results should prompt the clinician to confirm the diagnosis with the acetylcholine receptor antibody test and to refer this patient to a specialist (neurologist or neuro-ophthalmologist).Case 2The presentation of an elderly patient complaining of fluctuating double vision and weakness worsening toward the end of the day raises the possibility of myasthenia gravis. The lack of quiver eye movements, peek sign, or history of “unintelligible speech after prolonged speaking” or “food in the mouth after swallowing” does not significantly reduce the likelihood of myasthenia based on the studies we reviewed. This patient does not have any objective ptosis or visible diplopia, so provocative tests cannot be performed. A search should be undertaken for causes of nonspecific dizziness and generalized fatigue. If, however, he continues to complain of fluctuating double vision, he should be referred for specialist evaluation to rule out myasthenia despite normal physical examination findings.THE BOTTOM LINEThe presence of certain historical features (speech becoming unintelligible after prolonged periods) or signs (peek sign) may be useful in confirming the diagnosis of myasthenia gravis, though their absence does not rule it out. The ice test, the sleep test, and response to anticholinesterase agents (especially the edrophonium test) are useful in confirming the diagnosis and reduce the likelihood when results are negative. A positive test result should prompt proceeding with acetylcholine receptor antibody testing and specialist referral for electrophysiologic tests and should help confirm the diagnosis in patients who have negative results for the acetylcholine receptor antibody panel.This review has several limitations, and the results should be interpreted with caution. The results may not be generalizable for a number of reasons. Myasthenia gravis is a rare disorder, and the number of studies evaluating its symptoms and signs are few. The studies included in this review examined only a few symptoms and signs in a selected group of patients with a confirmed diagnosis of myasthenia gravis. Due to possible verification bias in this selected population of patients with myasthenia (in whom confirmation of the diagnosis is more likely with clear-cut cases), it is expected that in the general population these tests have a lower sensitivity but even higher specificity. Because of the uncertainty regarding sensitivity, patients with persistent symptoms but normal physical examination findings should be referred to specialists for diagnosis. The specificity and sensitivity of the described tests may also greatly depend on the skill and experience of the examiner. Future studies are needed that evaluate not only intraobserver variability but agreement between experts and nonexperts. There are other signs that may be more useful than those tested historically and that await scientific study. This review underscores the need for more studies to evaluate symptoms and signs predictive of myasthenia to improve physicians’ ability to recognize and evaluate patients at the time of presentation.Corresponding Author:Katalin Scherer, MD, DUMC Box 3403, Durham, NC 27710 (scher012@mc.duke.edu).Author Contributions: Dr Scherer had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Acquisition of data; administrative, technical, or material support: Scherer, Bedlack.Analysis and interpretation of data; critical revision of the manuscript for important intellectual content: Scherer, Bedlack, Simel.Drafting of the manuscript: Scherer, Simel.Study supervision: Bedlack, Simel.Financial Disclosures:None reported.Disclaimer:Dr Simel was not involved in the editorial evaluation or decision making regarding publication of this article.Acknowledgment:We thank D. B. Sanders, MD, J. A. Edlow, MD, and J. R. Lynch, MD, for critical review of the manuscript.REFERENCESLHPhillipsIIThe epidemiology of myasthenia gravis.Neurol Clin1994122632718041341LHPhillipsIIJCTornerEpidemiologic evidence for a changing natural history of myasthenia gravis.Neurology199647123312388909435MGiaghedduGPuggioniGSannaEpidemiological study of myasthenia gravis in Sardinia, Italy (1958-1986).Acta Neurol Scand1989793263332728857DBSandersPIAndrewsJFHowardJMMasseySeronegative myasthenia gravis.Neurology199748(suppl 5)S40S45LHPhillipsIIJCTornerMSAndersonGMCoxThe epidemiology of myasthenia gravis in central and western Virginia.Neurology199242188818931407568JMMasseyAcquired myasthenia gravis.Neurol Clin1997155775959227954RSBedlackDBSandersSteroid treatment for myasthenia gravis: steroids have an important role.Muscle Nerve20022511712111754196RMPascuzziHBCoslettTRJohnsLong-term corticosteroid treatment of myasthenia gravis: report of 116 patients.Ann Neurol1984152912986721451BKalbGMatellRPirskanenMLambeEpidemiology of myasthenia gravis: a population-based study in Stockholm, Sweden.Neuroepidemiology20022122122512207149EBeghiCAntozziAPBatocchiPrognosis of myasthenia gravis: a multicenter follow-up study of 844 patients.J Neurol Sci19911062132201802969JSWeizerAGLeeDKCoatsMyasthenia gravis with ocular involvement in older patients.Can J Ophthalmol200136263311227387FESomnierWTrojaborgNeurophysiological evaluation in myasthenia gravis: a comprehensive study of a complete patient population.Electroencephalogr Clin Neurophysiol19938973877683605KEOssermanPKornfeldECohenStudies in myasthenia gravis: review of two hundred eighty-two cases at The Mount Sinai Hospital, New York City.Arch Intern Med19581027281JFSimpsonMRWesterbergKRMageeMyasthenia gravis: an analysis of 295 cases.Acta Neurol Scand196642(suppl 23)1275957970FRomiGOSkeieJAAarliNEGilhusMuscle autoantibodies in subgroups of myasthenia gravis patients.J Neurol200024736937510896269SJOhDEKimRKuruogluRJBradleyDDwyerDiagnostic sensitivity of the laboratory tests in myasthenia gravis.Muscle Nerve1992157207241324429FMHowardJrVALennonJFinleyJMatsumotoLRElvebackClinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis.Ann N Y Acad Sci19875055265383479935MJGarleppPHKayRLDawkinsThe diagnostic significance of autoantibodies to the acetylcholine receptor.J Neuroimmunol198233373507174785JMLindstromMESeyboldVALennonSWhittinghamDDDuaneAntibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value.Neurology19762610541059988512DBDrachmanMyasthenia gravis.N Engl J Med1994330179718108190158SBorensteinJEDesmedtLocal cooling in myasthenia: improvement of neuromuscular failure.Arch Neurol197532152157164165HJOosterhuisThe ocular signs and symptoms of myasthenia gravis.Doc Ophthalmol1982523633787067604HJOosterhuisStudies in myasthenia gravis, I: a clinical study of 180 patients.J Neurol Sci196438512546JSneddonMyasthenia gravis: the difficult diagnosis.Br J Psychiatry198013692937357226HJOosterhuisAcquired blepharoptosis.Clin Neurol Neurosurg199698178681470DGCoganMyasthenia gravis: a review of the disease and a description of lid twitch as a characteristic sign.Arch Ophthalmol19657421722114318498DGCoganRDYeeJGittingerRapid eye movements in myasthenia gravis, I: clinical observations.Arch Ophthalmol19769410831085938289RHOsherRCGriggsOrbicularis fatigue: the “peek” sign of myasthenia gravis.Arch Ophthalmol197997677679426681GBBartleyJDBullockThe Tensilon test using a three-way stopcock and double syringe.Ophthal Plast Reconstr Surg1986295963154548EBIngSYIngTIngJARamockiThe complication rate of edrophonium testing for suspected myasthenia gravis.Can J Ophthalmol20003514114410812483HJVan DykLFlorenceThe Tensilon test: a safe office procedure.Ophthalmology1980872102127422259MESeyboldThe office Tensilon test for ocular myasthenia gravis.Arch Neurol1986438428433729766LPaduaEStalbergMLoMonacoAEvoliABatocchiPTonaliSFEMG in ocular myasthenia gravis diagnosis.Clin Neurophysiol20001111203120710880794KCKubisHVDanesh-MeyerPJSavinoRCSergottThe ice test versus the rest test in myasthenia gravis.Ophthalmology20001071995199811054320ACzaplinskiAJSteckPFuhrIce pack test for myasthenia gravis: a simple, noninvasive and safe diagnostic method.J Neurol200325088388412883938MErtasNAracKKumralTTuncbayIce test as a simple diagnostic aid for myasthenia gravis.Acta Neurol Scand1994892272298030407FDEllisCSHoytFJEllisARJefferyNSondhiExtraocular muscle responses to orbital cooling (ice test) for ocular myasthenia gravis diagnosis.J AAPOS2000427128111040476ALertchavanakulPGamnerdsiriPHirunwiwatkulIce test for ocular myasthenia gravis.J Med Assoc Thai200184(suppl 1)S131S13611529325KCGolnikRPenaAGLeeEREggenbergerAn ice test for the diagnosis of myasthenia gravis.Ophthalmology19991061282128610406606KDSethiMHRivnerTRSwiftIce pack test for myasthenia gravis.Neurology198737138313853614664JGOdelJMWinterkornMMBehrensThe sleep test for myasthenia gravis: a safe alternative to Tensilon.J Clin Neuroophthalmol1991112882921838552APBatocchiAEvoliLMajoliniOcular palsies in the absence of other neurological or ocular symptoms: analysis of 105 cases.J Neurol19972446396459402541GANicholsonJGMcLeodLRGriffithsComparison of diagnostic tests in myasthenia gravis.Clin Exp Neurol19831945496568927KEOssermanLIKaplanRapid diagnostic test for myasthenia gravis: increased muscle strength, without fasciculations, after intravenous administration of edrophonium (Tensilon) chloride.JAMA1952150265268RDYeeDGCoganDSZeeRWBalohVHonrubiaRapid eye movements in myasthenia gravis, II: electro-oculographic analysis.Arch Ophthalmol19769414651472962656FGWeijnenJBKuksAvan der BiltHWvan der GlasMWWassenbergFBosmanTongue force in patients with myasthenia gravis.Acta Neurol Scand200010230330811083507DRHollemanJrDLSimelDoes the clinical examination predict airflow limitation?JAMA19952733133197815660DMEddyVHasselbladRDShachterMeta-Analysis by the Confidence Profile Method: The Statistical Synthesis of Evidence.San Diego, Calif: Academic Press; 1992MBorensteinHRothsteinComprehensive Meta-analysis v1.0.23 [computer program].Englewood, NJ: Biostat; 1999RZJaeschkeMMeadeGGuattSKeenanDCookHow to use diagnostic test articles in the intensive care unit: diagnosing weanability using f/Vt.Crit Care Med199725151415219295825 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Does This Patient Have Myasthenia Gravis?

JAMA , Volume 293 (15) – Apr 20, 2005

Loading next page...
 
/lp/american-medical-association/does-this-patient-have-myasthenia-gravis-JD7ckClOER

References (47)

Publisher
American Medical Association
Copyright
Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.293.15.1906
pmid
15840866
Publisher site
See Article on Publisher Site

Abstract

ContextClinicians must be able to diagnose myasthenia gravis, since delays in establishing the diagnosis may put patients at risk for complications from this treatable disease.ObjectiveTo determine if items in the history and examination or results of simple tests change the likelihood of myasthenia gravis as a diagnosis.Data SourcesMEDLINE search of English-language articles (January 1966-January 2005) using the terms myasthenia gravis, diagnosis, and test, and a search of bibliographies of retrieved articles.Study SelectionStudies evaluating a particular symptom or sign in patients both with and without myasthenia gravis. Of 640 articles retrieved, 33 were eligible for review. Of these, 15 met inclusion criteria and form the basis of this review.Data ExtractionTwo authors independently reviewed each study to determine eligibility, abstracted data using a standardized instrument, and classified study quality using previously published criteria.Data SynthesisA history of “speech becoming unintelligible during prolonged speaking” and the presence of the peek sign increase the likelihood of myasthenia gravis (likelihood ratio [LR], 4.5; 95% confidence interval [CI], 1.2-17.0 and LR, 30.0; 95% CI, 3.2-278.0, respectively). Their absence does not significantly reduce the likelihood of myasthenia gravis. The identified studies only assessed 1 other historical feature and sign each (“food remaining in the mouth after swallowing” and quiver eye movements, respectively), and neither of these significantly changes the likelihood of myasthenia. The ice test is useful when the response is abnormal (summary positive LR, 24.0; 95% CI, 8.5-67.0) and diminishes the likelihood of myasthenia gravis when the response is normal (summary negative LR, 0.16; 95% CI, 0.09-0.27). A positive response to an anticholinesterase medication (mainly edrophonium test) increases the probability of a diagnosis of myasthenia gravis (summary positive LR, 15.0; 95% CI, 7.5-31.0), and a negative response reduces the diagnostic probability of myasthenia (summary negative LR, 0.11; 95% CI, 0.06-0.21). An abnormal sleep test result is useful in confirming the diagnosis (LR, 53.0; 95% CI, 3.4-832.0). The rest and sleep tests make the probability of myasthenia unlikely when results are normal (LR, 0.52; 95% CI, 0.29-0.95 and LR, 0.01; 95% CI, 0.00-0.16, respectively).ConclusionsItems in the history and physical examination along with results of certain simple tests performed in the office (ice test, sleep test, and edrophonium test) are useful in predicting the likelihood of myasthenia gravis. These results must be interpreted with caution, however, given the high prevalence of disease in the populations reported in clinical studies. This review is limited by the small number of signs and symptoms scientifically studied and reported in the literature. Future studies evaluating the value of common historical features and easy maneuvers commonly known and practiced by experts in the clinical diagnosis of myasthenia are needed.CLINICAL SCENARIOSCase 1A 45-year-old man has a 2-month history of fluctuating double vision, a “droopy” right eye that improves with rest, and a complaint that “food gets stuck halfway down.” Your examination confirms severe right eyelid ptosis that dramatically improves with rest. His right eye adduction and upgaze are markedly impaired. The left eye demonstrates complete horizontal ophthalmoplegia. The limb muscle strength and reflexes are normal. You wonder whether there is an accurate and clinically useful bedside test to help confirm the diagnosis of myasthenia gravis.Case 2A 69-year-old man has a 2-month history of intermittent spells of double vision, generalized weakness that worsens toward the evening, and unspecified dizziness. Although he has normal strength and reflexes and no ophthalmoplegia, he does report fluctuating diplopia during the examination. As in Case 1, you must decide whether to perform additional bedside tests, obtain electrodiagnostic or acetylcholine antibody testing, or pursue a broader diagnostic evaluation of the various causes of dizzy spells and fatigue.WHY IS THIS AN IMPORTANT QUESTION TO ANSWER WITH A CLINICAL EXAMINATION?Myasthenia gravis is an autoimmune disease associated with circulating acetylcholine receptor antibodies, modification of the synaptic cleft, and destruction of the postsynaptic neuromuscular membrane. The clinical hallmark of the disease is fatigable weakness. The clinical severity ranges from mild, purely ocular, forms to severe generalized weakness and respiratory failure. Myasthenia gravis is a rare disease; its prevalence in the United States is reported at 14.2/100 000. Prevalence rates have been increasing steadily over the past decades, likely due to decreased mortality, longer survival, and higher rates of diagnosis.Men older than 50 years have the highest incidence in the population, with the peak around age 70 years. Women have 2 incidence peaks: one around ages 20 to 40 years and one around age 70 years.Clinicians must be alert to the symptoms and signs of myasthenia gravis, as it is an eminently treatable disease and the earlier treatment is started, the better the clinical response.Only 54% to 69% of patients with myasthenia gravis are diagnosed within 1 year of onset, and the mean time to diagnosis is more than 1 year.Untreated patients are at risk for deterioration and “crisis,” which occurs when weakness becomes severe enough to require mechanical ventilation.Left untreated, reversible and fatigable weakness may become fixed. An erroneous diagnosis of myasthenia gravis may expose patients to unnecessary diagnostic procedures and treatments.The acetylcholine receptor antibody test is the most specific diagnostic test for myasthenia gravis. This test has reasonable sensitivity in generalized myasthenia gravis (80%-96%), but up to 50% of patients with purely ocular myasthenia are seronegative.Single-fiber electromyography, performed by highly trained experts at specialized centers, is highly sensitive for disorders of the neuromuscular junction but is not specific for myasthenia gravis.The purpose of this review was to determine the value of clinical symptoms and signs, as well as the results of simple provocative clinical tests, in deciding whether myasthenia gravis should be considered as a diagnosis and in enabling the physician to determine if further confirmatory testing (including the highly specific and sensitive antibody test) is warranted.Anatomical and Physiological Origins of the Symptoms and Signs Used to Answer This QuestionIn the normal neuromuscular junction acetylcholine is released into the synaptic cleft, diffuses to the postsynaptic membrane, binds to ligand-sensitive ion channels (nicotinic acetylcholine receptors), and causes an excitatory postsynaptic end-plate potential. If the threshold depolarization is achieved, an action potential will spread along the muscle fiber membrane, causing muscle contraction. Acetylcholine is cleared from the synaptic cleft by presynaptic reuptake and by the metabolic action of acetylcholinesterase (Figure 1).Figure 1.Neuromuscular JunctionIn patients with acetylcholine receptor (AChR) antibody–positive myasthenia gravis, circulating antibodies bind to the AChRs, which may block acetylcholine binding, lead to crosslinking of receptors promoting internalization and degradation, and induce postsynaptic membrane damage via complement activation. The number and availability of receptors are reduced such that end-plate potentials are insufficient to generate action potentials in a number of muscle fibers, causing weakness.The failure of transmission at many neuromuscular junctions in myasthenia results in diminished end-plate potentials that are insufficient to generate action potentials in a number of muscle fibers.This results in fatigable weakness of striated muscles, which is the basis for the clinical diagnosis. Sustained or repetitive muscle contraction causes fatigue and weakness of myasthenic muscles. Cooling a weak muscle improves neuromuscular transmission.Rest and acetylcholinesterase inhibitors transiently increase acetylcholine levels in the synaptic cleft. The change in strength following these manipulations can be assessed during the clinical examination.Symptoms and Signs and How to Elicit ThemPatients with myasthenia gravis complain of weakness in specific muscles. Up to 65% of patients initially have ocular symptoms of double vision and drooping of the eyelids. Less than one fourth of patients present with bulbar weakness (ie, in lower cranial nerve–innervated oropharyngeal muscles) and report slurred or nasal speech, alterations of the voice (eg, softness, breathiness, hoarseness), and difficulty chewing or swallowing. Limb weakness is a rare initial complaint (14%-27%) and should be differentiated from nonspecific generalized fatigue. Patients may report shortness of breath. The symptoms of myasthenia are typically better upon awakening or after rest and become progressively worse with prolonged use of the affected muscles or later in the day.Reduced muscle power by manual testing in specific muscles that worsens with repetition and improves with rest is the characteristic examination finding in myasthenia. Most muscles with voluntary activation have a large variability of strength even under normal conditions due to effort. Evaluating extremity strength greatly depends on the experience of the examiner. Ptosis and extraocular muscle deficits are relatively free of a voluntary component and provide a more objective measure.Fatigable and rapidly fluctuating asymmetric ptosis is a hallmark of myasthenia gravis. The rapid fluctuation results from improvement during even very short periods of rest, such as blinking. Besides fast variability in the degree of ptosis, it may altogether shift quickly from one eye to the other, known as “shifting ptosis.”Ptosis should be evaluated with the patient sitting comfortably, the head held in primary position without tilting. The patient fixates on a distant object (eg, a spot on the wall) and is asked to refrain from blinking and to relax the forehead muscles. Frontalis contraction, a mostly involuntary compensatory mechanism, is a common and characteristic sign in myasthenic patients with ptosis. Relaxing the forehead muscles may be difficult for some patients. The examiner measures palpebral fissure width at eye level during forward gaze and again during prolonged upward or lateral gaze for 30 seconds.The more ptotic eyelid should be used for additional provocative tests, such as the ice pack, rest, and sleep tests.The ice pack test is performed by placing a latex glove finger filled with crushed ice over the more ptotic eyelid for 2 minutes. During the rest test the patient places a glove filled with cotton (a placebo) over the more ptotic eyelid while holding the eyes closed for 2 minutes. During the sleep test the patient is left in a quiet dark room with the eyes closed for 30 minutes. Complete or almost complete resolution of ptosis or at least a 2-mm increase in palpebral fissure width constitutes a positive response to these maneuvers. It is very important to evaluate the improvement immediately following the test, as the lids may quickly begin to droop again.The curtain sign (also known as “enhanced ptosis” or “paradoxical ptosis”) is usually observed in patients with some initial ptosis. The patient looks straight ahead and refrains from blinking. The examiner holds one eye open, which results in the other lid starting to droop more (like a curtain falling). The lid twitch sign occurs when the patient opens the eyes after gentle closure or follows the examiner’s finger down and then back up to eye level. The lids overshoot or “twitch” for a fraction of a second before settling into position and starting to droop.Asymmetrical weakness of extraocular muscles is commonly observed in myasthenia when sustained lateral gaze or upgaze worsens or induces double vision. The cover-uncover test may be performed to bring out subtle extraocular weakness. As the patient fixates on an object in the distance, the examiner covers one eye while observing for deviation of the uncovered eye during lateral and then upward gazing. With extraocular weakness, the uncovered eye will drift. The examination is completed by repeating the procedure for the opposite eye. Quiver eye movements are very fast, small-twitch, “lightning-” or “jerk”-like movements of the eyes upon changing direction of gaze. They are said to occur even in the setting of profound ophthalmoplegia.Although patients rarely complain of facial weakness, it is often found on examination. Severe facial weakness results in a characteristic transverse smile. Orbicularis oculi weakness is demonstrated as the examiner tries to separate the eyelids against forced eye closure. Orbicularis oculi fatigue may be observed on gentle eye closure. After complete initial apposition of the lid margins, they separate within seconds and the white of the sclera starts to show (positive “peek sign”) (Figure 2).The iris should not be visible due to the eyeballs being rolled up (Bell phenomenon). The iris may be visible if the patient is not trying to close the eyes voluntarily (in the case of a conversion reaction and functional weakness) or in case of severe ophthalmoplegia.Figure 2.Peek SignOrbicularis oculi weakness may be indicated by a positive peek sign after gentle eyelid closure. After complete initial apposition of the lid margins, they quickly (within 30 seconds) start to separate and the sclera starts to show (ie, a positive peek sign). The presence of a peek sign increases the likelihood of myasthenia gravis (likelihood ratio, 30.0; 95% confidence interval, 3.2-278.0), but absence of the peek sign does not rule it out.Tongue and pharyngeal weakness will result in the patient’s speech becoming slurred or nasal, especially with prolonged speaking. Other commonly weak muscles include neck flexors, deltoids, hip flexors, finger/wrist extensors, and foot dorsiflexors. The muscles should be repeatedly tested against manual resistance, with a brief rest between repetitions. Having the patient hold the head above the pillow in the supine position or hold the arms outstretched in abduction at the shoulder for 1 minute are ways to test for fatigability of neck flexors and deltoids, respectively. Involvement is often asymmetrical. The remainder of the neurologic examination results, including those for deep tendon reflexes and sensory examination, must be normal.Anticholinesterase TestsEdrophonium chloride is a fast- and short-acting acetylcholinesterase inhibitor that may be administered in the office setting to diagnose myasthenia gravis (Box). Its effect usually occurs within 30 seconds and lasts less than 5 minutes. Most myasthenic muscles respond to the test dose of 2 mg, but many will require more. Adverse effects are rare and usually mild (excess salivation, sweating, abdominal cramps, or fecal incontinence). Serious adverse effects, such as bradycardia, asystole, and bronchoconstriction, occur infrequently (<0.2%) but warrant that the patient be receiving cardiac monitoring during the test and that a bag-mask be available should the patient need ventilatory assistance.Reactive airway disease or cardiac bradyarrhythmias are relative contraindications. Using a 3-way stopcock setup may be feasible in a patient already equipped with a peripheral intravenous line (in an intensive care unit, for example). One concern with such a setup is the possibility of an accidental mix-up of the syringes, with resultant injection errors—the syringes should always be labeled clearly. Due to the short action of the drug, the examiner must be able to quickly assess for improvement. Evaluating extraocular muscle abnormalities or changes in manual muscle testing require skill and time; therefore, most experts recommend performing the edrophonium test only when the patient has easily observed baseline weakness in specific muscles.One author feels that only a clearly ptotic eyelid or visibly abnormal extraocular muscles provide “objective” end points.Unequivocal improvement in ptosis or extraocular muscles constitutes a positive response. The administering physician (especially one with less experience) should consider blinding the edrophonium administration to avoid expectation bias.Box. Edrophonium TestEstablish reliable peripheral intravenous accessPrepare a syringe with 2 mg of atropine (available in 0.4-mg/mL or 1-mg/mL ampules) to have handyPrepare 1 mL (10 mg) of edrophonium in a tuberculin syringe (edrophonium is available in a 10-mg/mL solution in a 1-mL ampule [10 mg] or in a 10-mL vial [total of 100 mg])Inject 2 mg (0.2 mL) slowly over 15 seconds while observing for an objective improvement in target musclesImprovement should occur within 30 seconds and disappear in 5 minutes; if no response and no significant adverse effects, administer the remaining edrophonium (8 mg [0.8 mL]) for a total dose of 10 mgAtropine should be injected (0.5 or 1 mg) in case of clinically significant bradycardia, respiratory distress, or syncope**Routine administration of atropine simultaneously with edrophonium for the purpose of diagnostic testing for myasthenia gravis is not recommended. Bartley and Bullockrecommend using a 3-way stopcock with the edrophonium-containing syringe attached to the direct port and the atropine-containing syringe attached to the side port, so that atropine may be quickly injected in case of severe adverse effects.Neostigmine bromide is an anticholinesterase agent used to treat myasthenia gravis. Parenteral preparations are available in vials containing 0.25-, 0.5-, and 1-mg/mL doses. The recommended dose for the diagnosis of myasthenia is 0.02 mg/kg given intramuscularly. A standard dose of 1 or 1.5 mg may be used. The response should be evaluated 30 minutes after injection, at the time of peak effect. The half-life after intramuscular administration is 50 to 90 minutes. Adverse effects, precautions, and need for good intravenous access (to administer atropine in case of an adverse event) are the same as for edrophonium.Pyridostigmine bromide is an analog of neostigmine with a slightly longer duration of action and fewer adverse effects. It is the most commonly used anticholinesterase agent for the symptomatic treatment of myasthenia gravis. It has been used for diagnosis in patients in whom edrophonium or neostigmine is relatively contraindicated though it is not generally used for diagnostic purposes.It is available for injection in 2-mL vials containing 5 mg/mL. A 2-mg intramuscular or intravenous dose is equivalent to 60 mg orally. Precautions should be exercised just as with edrophonium and neostigmine.METHODSSearch Strategy and Quality ReviewEnglish-language articles in the MEDLINE database from January 1966 through January 2005 were searched using the terms myasthenia gravis, diagnosis,and test. One of the authors (K.S.) identified potential articles by screening the retrieved titles and abstracts (when available) and searching through the bibliographies of the retrieved articles. Two authors (K.S., R.S.B.) independently reviewed the retrieved articles. An article was included where agreement existed that the study had met our inclusion criteria.Eligible studies evaluated a particular symptom or sign in patients with myasthenia gravis and in controls. Studies requiring sophisticated equipment or subspecialty trained physicians (otolaryngology, ophthalmology, etc) were excluded. Studies based on small numbers of patients were not excluded, as most series are comparatively small in the literature. Out of 640 total articles, the search identified 33 potential articles. Of these, 15 met inclusion criteria and form the basis of this review.Quality of evidence in each study was classified based on a published classification scheme for levels of evidence developed for The Rational Clinical Examination series (Table 1). In addition, studies that were carried out prospectively and/or on a consecutive series of patients were ranked higher (Table 2). Only 2 studies included an independent blinded comparison of signs and symptoms to a criterion standard.Table 1.Levels of Evidence*RecommendationLevel of EvidenceDefinitionGrade A1Independent, blinded comparison of sign or symptom results with a criterion standard of diagnosis among a large number of consecutive patients suspected of having the target conditionGrade B2Independent, blinded comparison of sign or symptom with a criterion standard of diagnosis among a small number of consecutive patients suspected of having the target conditionGrade C3Independent, blinded comparison of sign or symptom with a criterion standard of diagnosis among nonconsecutive patients suspected of having the target condition4Nonindependent comparison of sign or symptom with a criterion standard of diagnosis among samples of patients who obviously have the target condition plus, perhaps, normal individuals5Nonindependent comparison of sign or symptom with a standard of uncertain validity*Modified from Holleman and Simel.Table 2.Characteristics of Studies That Include Patients With Myasthena Gravis as Well as ControlsSourceEnrollmentPatient SelectionPatients With Myasthenia Gravis, No./Overall (%)Diagnostic Criteria for Myasthenia GravisSymptom or Sign Studied (Inclusion Criteria)Enrollment SiteEvidence Level 2Kubis et al,2000ProspectiveConsecutive10/25 (40)AChRAb or SFEMGIce test, rest test (ptosis)Neuro-ophthalmology clinicEvidence Level 3Ertas et al,1994ProspectiveUnclear12/27 (44)GestaltIce test, edrophonium or neostigmine test (ptosis)Neurology clinicCzaplinski et al,2003ProspectiveUnclear5/10 (50)AChRAb and RNSIce test, edrophonium test (ptosis)Neurology clinicEvidence Level 4Sethi et al,1987UnclearUnclear10/17 (59)GestaltIce test, edrophonium test (ptosis)Neurology clinicOdel et al,1991UnclearUnclear42/68 (62)Edrophonium testSleep test (ptosis or ophthalmoplegia)Ophthalmology clinicGolnik et al,1999ProspectiveUnclear20/40 (50)AChRAb or edrophonium testIce test (ptosis)Neuro-ophthalmology clinicEllis et al,2000ProspectiveConsecutive15/30 (50)GestaltIce test (ptosis or abnormal extraocular movements)Ophthalmology clinicLertchavanakul et al,2001ProspectiveUnclear20/40 (50)EMG or neostigmine testIce test (ptosis)Ophthalmology clinicEvidence Level 5Osserman and Kaplan,1952ProspectiveUnclear15/50 (30)GestaltEdrophonium testNeurology clinic, hospitalYee et al,1976ProspectiveUnclear10/18 (56)Edrophonium or neostigmine testQuiver eye movements (ophthalmoplegia)Ophthalmology clinicOsher and Griggs,1979ProspectiveConsecutive25/275 (9)UnclearPeek sign (orbicularis oculi fatigue)Ophthalmology clinicNicholson et al,1983ProspectiveConsecutive46/75 (61)Gestalt with 1 positive test resultEdrophonium testAchRab laboratoryBatocchi et al,1997ProspectiveConsecutive39/72 (54)Gestalt with 2 positive test resultsEdrophonium test (ptosis, ophthalmoplegia)Ophthalmology clinicPadua et al,2000ProspectiveConsecutive29/69 (42)AChRAb + SFEMG or RNS + AChEIEdrophonium or pyridostigmine testNeurology clinicWeijnen et al,2000UnclearUnclear60/80 (75)GestaltFood in mouth after swallowing, unintelligible speech after prolonged speakingOromaxillofacial surgery clinicAbbreviations: AChRAb, acetylcholine receptor antibody; AChEI, acetylcholine esterase inhibitor; EMG, electromyography; Gestalt, overall clinical impression; RNS, repetitive nerve stimulation; SFEMG, single-fiber electromyography.Statistical MethodsSensitivity was defined as the proportion of patients with myasthenia gravis who had the particular symptom or sign; specificity, as the proportion of nonmyasthenic patients without the sign or symptom. The positive likelihood ratio (LR) was defined as the likelihood of a positive test result (or presence of a sign or symptom) in a myasthenic patient compared with the likelihood of a positive test result in a nonmyasthenic patient, that is, the increase in odds that the patient has myasthenia gravis when the test result is positive (or when the sign or symptom is present). Positive LR is expressed as sensitivity/(1 − specificity). The negative LR is the likelihood of a negative test result (or absence of a sign or symptom) in a myasthenic patient compared with the likelihood of a negative test result (or absence of a sign or symptom) in a nonmyasthenic patient, that is, the decrease in odds that the patient has myasthenia gravis when the test result is negative (or when the sign or symptom is absent). Negative LR is expressed as (1 − sensitivity)/specificity. Summary LRs were derived using random-effects measures that provide conservative confidence intervals (CIs) around the estimates.RESULTSFifteen studies reported findings on patients both with and without myasthenia gravis(Table 2). Seven studies evaluated the ice test, including 3 that also evaluated the response to anticholinesterase agents and 1 that also evaluated the rest test. Four additional studies reported on the response to anticholinesterase agents and 1 additional study on the sleep test. The remaining 3 articles included 1 study reporting on 2 symptoms and 2 studies evaluating 1 sign each. The results across studies for the ice test and anticholinesterase tests were homogeneous; we report random-effects summary LRs for these signs (Table 3).Table 3.Clinical Signs and Symptoms and Results of Clinical Tests in the Prediction of Myasthenia GravisSourceLR (95% CI)PositiveNegativeSymptomsFood in mouth after swallowingWeijnen et al13.0 (0.85-212.0)0.70 (0.58-0.84)Unintelligible speech after prolonged speakingWeijnen et al4.5 (1.2-17.0)0.61 (0.46-0.80)SignsPeek signOsher and Griggs30.0 (3.2-278.0)0.88 (0.76-1.0)Quiver eye movementsYee et al4.1 (0.22-75.0)0.82 (0.57-1.2)Simple Office TestsIce testKubis et al28.0 (1.8-427.0)0.14 (0.03-0.62)Ertas et al31.0 (2.0-472.0)0.04 (0.00-0.61)Czaplinski et al11.0 (0.77-158.0)0.09 (0.01-1.3)Sethi et al12.0 (0.83-185.0)0.24 (0.08-0.72)Golnik et al33.0 (2.1-515.0)0.22 (0.10-0.50)Ellis et al31.0 (2.0-475.0)0.03 (0.00-0.46)Lertchavanakul et al39.0 (2.5-605.0)0.07 (0.01-0.33)Summary24.0 (8.5-67.0)0.16 (0.09-0.27)Anticholinesterase testErtas et al28.0 (1.8-436.0)0.12 (0.03-0.54)Czaplinski et al9.0 (0.61-133.0)0.27 (0.07-1.1)Sethi et al12.0 (0.83-185.0)0.24 (0.08-0.72)Osserman and Kaplan70.0 (4.4-1096.0)0.03 (0.00-0.46)Nicholson et al54.0 (3.5-850.0)0.10 (0.04-0.24)Batocchi et al67.0 (4.3-1053.0)0.01 (0.00-0.16)Padua et al9.7 (3.8-25.0)0.04 (0.01-0.28)Summary15.0 (7.5-31.0)0.11 (0.06-0.21)Rest testKubis et al16.0 (0.98-261.0)0.52 (0.29-0.95)Sleep testOdel et al53.0 (3.4-832.0)0.01 (0.00-0.16)Abbreviations: CI, confidence interval; LR, likelihood ratio.Accuracy of Symptoms for the Diagnosis of Myasthenia GravisOnly 1 eligible study was identified and it evaluated 2 symptoms.The history was taken from patients via a questionnaire. The presence of food remaining in the mouth after swallowing increases the likelihood of myasthenia gravis, but the wide CI indicates that the finding is not reliable. Speech becoming unintelligible during prolonged speaking has an LR of 4.5 (95% CI, 1.2-17.0). Neither normal swallowing nor normal speech rules out myasthenia gravis (LR, 0.70; 95% CI, 0.58-0.84 and LR, 0.61; 95% CI, 0.46-0.80, respectively).Accuracy of Signs for the Diagnosis of Myasthenia GravisTwo eligible studies were identified and reported on 1 sign each.The presence or absence of quiver eye movements increased the likelihood of myasthenia gravis, but the broad CIs around the LR indicate that the examiner may not rely on the finding. The presence of the peek sign might be more useful (LR, 30.0; 95% CI, 3.2-278.0) but also has broad CIs.Accuracy of Simple Office Tests for the Diagnosis of Myasthenia GravisSeven studies investigated the ice test and all had similar findings.The overall prevalence (prior probability) of myasthenia gravis in these studies was 49% (92 of 189 patients total). All but 1 of these studies were carried out prospectively. The LR for a positive ice test result suggests that the finding is useful (summary LR, 24.0; 95% CI, 8.5-67.0). A negative ice test result lessens the likelihood of myasthenia gravis (summary LR, 0.16; 95% CI, 0.09-0.27).Two studies evaluated the precision (ie, interobserver variation) of the ice test. Kubis et alused the signed-rank test to evaluate interobserver variability and found no significant difference between observers (P = .79). Ertas et alreported complete agreement among their observers. Neither of the studies evaluated the intraobserver variation.Seven studies reported the results of anticholinesterase tests, and all had similar findings.Five of these studies evaluated the edrophonium test; 1 study included response to pyridostigmine, and another included response to neostigmine as an alternative. All but 1 of these studies were prospective and 3 were carried out on consecutive patients. One hundred fifty-six of 320 patients (49%) had myasthenia gravis. The likelihood of myasthenia gravis increases for a positive test result (summary LR, 15.0; 95% CI, 7.5-31.0), whereas the lack of improvement makes myasthenia gravis much less likely (summary LR, 0.11; 95% CI, 0.06-0.21).Two studies evaluated the sleep or rest test on 93 patients, including 52 (56%) with myasthenia gravis.An abnormal rest test result increases the likelihood of myasthenia but the wide CI indicates uncertainty about the true significance. A positive sleep test result may be more useful (LR, 53.0; 95% CI, 3.43-832.0). Both the rest and sleep test make the probability of myasthenia unlikely when the result is normal (LR, 0.52; 95% CI, 0.29-0.95 and LR, 0.01; 95% CI, 0.00-0.16, respectively).Are These Symptoms or Signs Ever Normal?Fluctuating weakness (ie, reduced muscle power) that worsens with exertion and improves with rest or with application of ice or cold is never normal. It is important to differentiate fluctuating weakness from patients’ reports of “weakness,” which most often refers to fatigue or exertion. True fluctuating weakness, as demonstrated by manual muscle testing, is the cardinal feature of myasthenia gravis. Other neuromuscular conditions (including amyotrophic lateral sclerosis and periodic paralyses) may be associated with fluctuating weakness; however, the fluctuation in myasthenia is more dramatic and occurs much more rapidly. Ptosis or diplopia may be present in a number of conditions (congenital exotropia or esotropia, strabismus, congenital ptosis, cranial nerve palsies, myopathies, progressive external ophthalmoplegia, brainstem lesions, and neurodegenerative disorders such as progressive supranuclear palsy), but the constant degree of involvement and associated neurologic findings (pupillary abnormalities, nystagmus, vertigo, sensory involvement) commonly exclude myasthenia gravis as a diagnosis. One must bear in mind that even the initially fluctuating weakness of myasthenia gravis will become fixed over time if severe enough. The hypomimia (“masked facies”) of parkinsonism may be mistaken for facial weakness, but on examination no true weakness is found and associated features of parkinsonism are evident. It may be a challenge to differentiate true fatigable weakness due to myasthenia gravis from conversion reactions. In the latter conditions one may often find that various elements of the examination are inconsistent with pathophysiologic conditions. Conversion reactions commonly produce “give-away” weakness, in which an initial full resistance suddenly gives away under the hand of the examiner, as opposed to true weakness that gradually worsens or is present from the start. Ptosis produced by conversion reactions is commonly symmetrical and bilateral. Since it occurs with contraction of the orbicularis oculi, one can observe that the lower lid elevates. It may completely disappear with diverting the patient’s attention. Eye closure weakness due to poor effort results in the iris showing between the eyelids.RESOLUTION OF CLINICAL SCENARIOSCase 1Fluctuating diplopia and ptosis are highly characteristic of myasthenia gravis. The presence of a positive rest test result may increase the likelihood of myasthenia. The physician must carefully question the patient regarding his complaint of “food getting stuck halfway down.” If it is food remaining in the mouth after swallowing, it may also increase the probability of myasthenia. The available evidence-based data, however, do not allow the examiner to rely on these findings to confirm the diagnosis. These positive test results should prompt the clinician to confirm the diagnosis with the acetylcholine receptor antibody test and to refer this patient to a specialist (neurologist or neuro-ophthalmologist).Case 2The presentation of an elderly patient complaining of fluctuating double vision and weakness worsening toward the end of the day raises the possibility of myasthenia gravis. The lack of quiver eye movements, peek sign, or history of “unintelligible speech after prolonged speaking” or “food in the mouth after swallowing” does not significantly reduce the likelihood of myasthenia based on the studies we reviewed. This patient does not have any objective ptosis or visible diplopia, so provocative tests cannot be performed. A search should be undertaken for causes of nonspecific dizziness and generalized fatigue. If, however, he continues to complain of fluctuating double vision, he should be referred for specialist evaluation to rule out myasthenia despite normal physical examination findings.THE BOTTOM LINEThe presence of certain historical features (speech becoming unintelligible after prolonged periods) or signs (peek sign) may be useful in confirming the diagnosis of myasthenia gravis, though their absence does not rule it out. The ice test, the sleep test, and response to anticholinesterase agents (especially the edrophonium test) are useful in confirming the diagnosis and reduce the likelihood when results are negative. A positive test result should prompt proceeding with acetylcholine receptor antibody testing and specialist referral for electrophysiologic tests and should help confirm the diagnosis in patients who have negative results for the acetylcholine receptor antibody panel.This review has several limitations, and the results should be interpreted with caution. The results may not be generalizable for a number of reasons. Myasthenia gravis is a rare disorder, and the number of studies evaluating its symptoms and signs are few. The studies included in this review examined only a few symptoms and signs in a selected group of patients with a confirmed diagnosis of myasthenia gravis. Due to possible verification bias in this selected population of patients with myasthenia (in whom confirmation of the diagnosis is more likely with clear-cut cases), it is expected that in the general population these tests have a lower sensitivity but even higher specificity. Because of the uncertainty regarding sensitivity, patients with persistent symptoms but normal physical examination findings should be referred to specialists for diagnosis. The specificity and sensitivity of the described tests may also greatly depend on the skill and experience of the examiner. Future studies are needed that evaluate not only intraobserver variability but agreement between experts and nonexperts. There are other signs that may be more useful than those tested historically and that await scientific study. This review underscores the need for more studies to evaluate symptoms and signs predictive of myasthenia to improve physicians’ ability to recognize and evaluate patients at the time of presentation.Corresponding Author:Katalin Scherer, MD, DUMC Box 3403, Durham, NC 27710 (scher012@mc.duke.edu).Author Contributions: Dr Scherer had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Acquisition of data; administrative, technical, or material support: Scherer, Bedlack.Analysis and interpretation of data; critical revision of the manuscript for important intellectual content: Scherer, Bedlack, Simel.Drafting of the manuscript: Scherer, Simel.Study supervision: Bedlack, Simel.Financial Disclosures:None reported.Disclaimer:Dr Simel was not involved in the editorial evaluation or decision making regarding publication of this article.Acknowledgment:We thank D. B. Sanders, MD, J. A. Edlow, MD, and J. R. Lynch, MD, for critical review of the manuscript.REFERENCESLHPhillipsIIThe epidemiology of myasthenia gravis.Neurol Clin1994122632718041341LHPhillipsIIJCTornerEpidemiologic evidence for a changing natural history of myasthenia gravis.Neurology199647123312388909435MGiaghedduGPuggioniGSannaEpidemiological study of myasthenia gravis in Sardinia, Italy (1958-1986).Acta Neurol Scand1989793263332728857DBSandersPIAndrewsJFHowardJMMasseySeronegative myasthenia gravis.Neurology199748(suppl 5)S40S45LHPhillipsIIJCTornerMSAndersonGMCoxThe epidemiology of myasthenia gravis in central and western Virginia.Neurology199242188818931407568JMMasseyAcquired myasthenia gravis.Neurol Clin1997155775959227954RSBedlackDBSandersSteroid treatment for myasthenia gravis: steroids have an important role.Muscle Nerve20022511712111754196RMPascuzziHBCoslettTRJohnsLong-term corticosteroid treatment of myasthenia gravis: report of 116 patients.Ann Neurol1984152912986721451BKalbGMatellRPirskanenMLambeEpidemiology of myasthenia gravis: a population-based study in Stockholm, Sweden.Neuroepidemiology20022122122512207149EBeghiCAntozziAPBatocchiPrognosis of myasthenia gravis: a multicenter follow-up study of 844 patients.J Neurol Sci19911062132201802969JSWeizerAGLeeDKCoatsMyasthenia gravis with ocular involvement in older patients.Can J Ophthalmol200136263311227387FESomnierWTrojaborgNeurophysiological evaluation in myasthenia gravis: a comprehensive study of a complete patient population.Electroencephalogr Clin Neurophysiol19938973877683605KEOssermanPKornfeldECohenStudies in myasthenia gravis: review of two hundred eighty-two cases at The Mount Sinai Hospital, New York City.Arch Intern Med19581027281JFSimpsonMRWesterbergKRMageeMyasthenia gravis: an analysis of 295 cases.Acta Neurol Scand196642(suppl 23)1275957970FRomiGOSkeieJAAarliNEGilhusMuscle autoantibodies in subgroups of myasthenia gravis patients.J Neurol200024736937510896269SJOhDEKimRKuruogluRJBradleyDDwyerDiagnostic sensitivity of the laboratory tests in myasthenia gravis.Muscle Nerve1992157207241324429FMHowardJrVALennonJFinleyJMatsumotoLRElvebackClinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis.Ann N Y Acad Sci19875055265383479935MJGarleppPHKayRLDawkinsThe diagnostic significance of autoantibodies to the acetylcholine receptor.J Neuroimmunol198233373507174785JMLindstromMESeyboldVALennonSWhittinghamDDDuaneAntibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value.Neurology19762610541059988512DBDrachmanMyasthenia gravis.N Engl J Med1994330179718108190158SBorensteinJEDesmedtLocal cooling in myasthenia: improvement of neuromuscular failure.Arch Neurol197532152157164165HJOosterhuisThe ocular signs and symptoms of myasthenia gravis.Doc Ophthalmol1982523633787067604HJOosterhuisStudies in myasthenia gravis, I: a clinical study of 180 patients.J Neurol Sci196438512546JSneddonMyasthenia gravis: the difficult diagnosis.Br J Psychiatry198013692937357226HJOosterhuisAcquired blepharoptosis.Clin Neurol Neurosurg199698178681470DGCoganMyasthenia gravis: a review of the disease and a description of lid twitch as a characteristic sign.Arch Ophthalmol19657421722114318498DGCoganRDYeeJGittingerRapid eye movements in myasthenia gravis, I: clinical observations.Arch Ophthalmol19769410831085938289RHOsherRCGriggsOrbicularis fatigue: the “peek” sign of myasthenia gravis.Arch Ophthalmol197997677679426681GBBartleyJDBullockThe Tensilon test using a three-way stopcock and double syringe.Ophthal Plast Reconstr Surg1986295963154548EBIngSYIngTIngJARamockiThe complication rate of edrophonium testing for suspected myasthenia gravis.Can J Ophthalmol20003514114410812483HJVan DykLFlorenceThe Tensilon test: a safe office procedure.Ophthalmology1980872102127422259MESeyboldThe office Tensilon test for ocular myasthenia gravis.Arch Neurol1986438428433729766LPaduaEStalbergMLoMonacoAEvoliABatocchiPTonaliSFEMG in ocular myasthenia gravis diagnosis.Clin Neurophysiol20001111203120710880794KCKubisHVDanesh-MeyerPJSavinoRCSergottThe ice test versus the rest test in myasthenia gravis.Ophthalmology20001071995199811054320ACzaplinskiAJSteckPFuhrIce pack test for myasthenia gravis: a simple, noninvasive and safe diagnostic method.J Neurol200325088388412883938MErtasNAracKKumralTTuncbayIce test as a simple diagnostic aid for myasthenia gravis.Acta Neurol Scand1994892272298030407FDEllisCSHoytFJEllisARJefferyNSondhiExtraocular muscle responses to orbital cooling (ice test) for ocular myasthenia gravis diagnosis.J AAPOS2000427128111040476ALertchavanakulPGamnerdsiriPHirunwiwatkulIce test for ocular myasthenia gravis.J Med Assoc Thai200184(suppl 1)S131S13611529325KCGolnikRPenaAGLeeEREggenbergerAn ice test for the diagnosis of myasthenia gravis.Ophthalmology19991061282128610406606KDSethiMHRivnerTRSwiftIce pack test for myasthenia gravis.Neurology198737138313853614664JGOdelJMWinterkornMMBehrensThe sleep test for myasthenia gravis: a safe alternative to Tensilon.J Clin Neuroophthalmol1991112882921838552APBatocchiAEvoliLMajoliniOcular palsies in the absence of other neurological or ocular symptoms: analysis of 105 cases.J Neurol19972446396459402541GANicholsonJGMcLeodLRGriffithsComparison of diagnostic tests in myasthenia gravis.Clin Exp Neurol19831945496568927KEOssermanLIKaplanRapid diagnostic test for myasthenia gravis: increased muscle strength, without fasciculations, after intravenous administration of edrophonium (Tensilon) chloride.JAMA1952150265268RDYeeDGCoganDSZeeRWBalohVHonrubiaRapid eye movements in myasthenia gravis, II: electro-oculographic analysis.Arch Ophthalmol19769414651472962656FGWeijnenJBKuksAvan der BiltHWvan der GlasMWWassenbergFBosmanTongue force in patients with myasthenia gravis.Acta Neurol Scand200010230330811083507DRHollemanJrDLSimelDoes the clinical examination predict airflow limitation?JAMA19952733133197815660DMEddyVHasselbladRDShachterMeta-Analysis by the Confidence Profile Method: The Statistical Synthesis of Evidence.San Diego, Calif: Academic Press; 1992MBorensteinHRothsteinComprehensive Meta-analysis v1.0.23 [computer program].Englewood, NJ: Biostat; 1999RZJaeschkeMMeadeGGuattSKeenanDCookHow to use diagnostic test articles in the intensive care unit: diagnosing weanability using f/Vt.Crit Care Med199725151415219295825

Journal

JAMAAmerican Medical Association

Published: Apr 20, 2005

There are no references for this article.